EA014182B1 - КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ - Google Patents

КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ Download PDF

Info

Publication number
EA014182B1
EA014182B1 EA200700249A EA200700249A EA014182B1 EA 014182 B1 EA014182 B1 EA 014182B1 EA 200700249 A EA200700249 A EA 200700249A EA 200700249 A EA200700249 A EA 200700249A EA 014182 B1 EA014182 B1 EA 014182B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
antibody
cell
individual
antibodies
Prior art date
Application number
EA200700249A
Other languages
English (en)
Russian (ru)
Other versions
EA200700249A1 (ru
Inventor
Серен Кофод Расмуссен
Анне Бонгор Толструп
Серен Брегенхолт Фредериксен
Йохн Хаурум
Original Assignee
Симфоген А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симфоген А/С filed Critical Симфоген А/С
Publication of EA200700249A1 publication Critical patent/EA200700249A1/xx
Publication of EA014182B1 publication Critical patent/EA014182B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA200700249A 2004-07-20 2005-07-18 КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ EA014182B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401133 2004-07-20
DKPA200401992 2004-12-22
PCT/DK2005/000501 WO2006007850A1 (en) 2004-07-20 2005-07-18 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture

Publications (2)

Publication Number Publication Date
EA200700249A1 EA200700249A1 (ru) 2007-06-29
EA014182B1 true EA014182B1 (ru) 2010-10-29

Family

ID=35159789

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700249A EA014182B1 (ru) 2004-07-20 2005-07-18 КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ

Country Status (13)

Country Link
US (2) US8198415B2 (enExample)
EP (2) EP1967529A1 (enExample)
JP (1) JP4926054B2 (enExample)
KR (1) KR20070038556A (enExample)
AU (1) AU2005263331B8 (enExample)
BR (1) BRPI0513706A (enExample)
CA (1) CA2574062A1 (enExample)
EA (1) EA014182B1 (enExample)
IL (1) IL179658A (enExample)
MX (1) MX2007000644A (enExample)
NO (1) NO20070927L (enExample)
NZ (1) NZ552265A (enExample)
WO (1) WO2006007850A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770654C1 (ru) * 2021-06-17 2022-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EA013225B1 (ru) * 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
NZ578851A (en) 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
CA2678628A1 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
BRPI0812091A2 (pt) * 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
AU2008295248A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-RSV antibodies
US20090093004A1 (en) * 2007-10-04 2009-04-09 Symphogen A/S Potency assay
WO2009065414A1 (en) * 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110047258A (ko) * 2008-08-26 2011-05-06 심포젠 에이/에스 저혈소판증의 치료 방법
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
CN102265152A (zh) * 2008-10-06 2011-11-30 西福根有限公司 鉴定和选择用于组合药品的药物候选物
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
BR112012007815A2 (pt) 2009-10-09 2018-03-20 Symphogen As quantificação multiplex de proteínas recombinantes em uma mistura por peptídeos de assinatura e espectrometria de massa.
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
DK2864346T3 (en) * 2012-06-21 2019-02-04 Synthon Biopharmaceuticals Bv Method of purifying an antibody.
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
US12247065B2 (en) * 2018-06-22 2025-03-11 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN113661173B (zh) 2019-03-29 2024-10-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
US12479908B2 (en) 2019-03-29 2025-11-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (PD1) and uses thereof
AU2020297940A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3140297A1 (en) 2019-06-19 2020-12-24 Simon Auslaender Method for the generation of a protein expressing cell by targeted integration using cre mrna
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2020254351A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220024637A (ko) 2019-06-19 2022-03-03 에프. 호프만-라 로슈 아게 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
AU2024328783A1 (en) * 2023-08-23 2026-03-12 Australian Red Cross Society Anti-rhesus d human monoclonal antibodies
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用
WO2026132369A1 (en) 2024-12-22 2026-06-25 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific fragment antigen binding expressing mammalian cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
WO2004061104A2 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
GB8906129D0 (en) 1989-03-17 1989-05-04 Central Blood Lab Authority Pharmaceutical preparations
GB8919761D0 (en) 1989-09-01 1989-10-18 Central Blood Lab Authority Chemical compounds
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
FI940811L (fi) 1992-06-26 1994-02-21 Aetsrn Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat
AU679949B2 (en) 1992-10-21 1997-07-17 Stefan Miltenyi Direct selection of cells by secretion product
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
PT1034262E (pt) 1997-11-18 2005-10-31 Pioneer Hi Bred Int Composicoes e metodos para a modificacao genetica de plantas
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
DE60044142D1 (de) 1999-07-23 2010-05-20 Univ California Dna-rekombination in eukaryotischen zellen mittels des rekombinationszentrums vom bakteriophag phic31
EP1106625A1 (en) 1999-11-17 2001-06-13 ZLB Bioplasma AG Rhesus D specific peptide sequences
MXPA02007664A (es) 2000-02-08 2004-08-23 Univ Michigan Separacion y representacion de proteinas.
EP1385869A2 (en) 2000-02-08 2004-02-04 The Regents Of The University Of Michigan Protein mapping
MXPA02007665A (es) 2000-02-08 2004-08-23 Univ Michigan Trazado de despliegue diferencial de proteinas.
CN1437482A (zh) 2000-05-26 2003-08-20 西福根有限公司 用于治疗变态反应的重组的或纯化的多克隆抗体
BR0112633A (pt) 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2002052259A1 (en) 2000-12-26 2002-07-04 The Institute For Systems Biology Rapid and quantitative proteome analysis and related methods
WO2003102539A2 (en) 2002-05-31 2003-12-11 The Regents Of The University Of Michigan Automated protein analysis system comprising capillary electrophoresis-tandem mass spectrometry
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
WO2004035169A2 (en) 2002-10-15 2004-04-29 The Regents Of The University Of Michigan Multidimensional protein separation system
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5789208A (en) * 1994-01-31 1998-08-04 The Trustees Of Boston University Polyclonal antibody libraries
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
WO2004061104A2 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREGENHOLT S. ET AL.: "PATHOGEN-SPECIFIC RECOMBINANT HUMAN POLYCLONAL ANTIBODIES: BIODEFENCE APPLICATIONS". EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 4, no. 3, March 2004 (2004-03), pages 387-396, XP008030716, ISSN: 1471-2598, the whole document *
HAURUM JOHN ET AL.: "Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle". IDRUGS: THE INVESTIGATIONAL DRUGS JOURNAL. MAY 2005, vol. 8, no. 5, May 2005 (2005-05), pages 404-409, XP002352885, ISSN: 1369-7056, the whole document *
SELINGER M.: "Immunoprophylaxis for rhesus disease-expensive but worth it?". BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY. JUN. 1991, vol. 98, no. 6, June 1991 (1991-06), pages 509-512, XP009056635, ISSN: 0306-5456, the whole document *
SHARON J. ET AL.: "CONSTRUCTION OF POLYCLONAL ANTIBODY LIBRARIES USING PHAGE DISPLAY". METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC., CLIFTON, NJ, US, vol. 178, 2002, pages 101-112, XP008053600, the whole document *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770654C1 (ru) * 2021-06-17 2022-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе

Also Published As

Publication number Publication date
EP1771483A1 (en) 2007-04-11
US8198415B2 (en) 2012-06-12
US20090017017A1 (en) 2009-01-15
JP4926054B2 (ja) 2012-05-09
BRPI0513706A (pt) 2008-05-13
JP2008509658A (ja) 2008-04-03
IL179658A (en) 2011-08-31
NO20070927L (no) 2007-04-19
NZ552265A (en) 2009-04-30
IL179658A0 (en) 2007-05-15
WO2006007850A1 (en) 2006-01-26
AU2005263331A1 (en) 2006-01-26
US20120322690A1 (en) 2012-12-20
EP1967529A1 (en) 2008-09-10
AU2005263331B2 (en) 2011-05-26
KR20070038556A (ko) 2007-04-10
EA200700249A1 (ru) 2007-06-29
AU2005263331A8 (en) 2011-06-16
CA2574062A1 (en) 2006-01-26
MX2007000644A (es) 2007-03-28
AU2005263331B8 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
UA129980C2 (uk) Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
JP4926054B2 (ja) 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
EP1448602B1 (en) Modified anti-tnf alpha antibody
US6605448B1 (en) Method and means for sorting and identifying biological information
KR101555658B1 (ko) 재조합 폴리클로날 단백질의 제조 방법
US8512703B2 (en) Idiotypic vaccine
EA030259B1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
TW200812616A (en) Binding polypeptides with optimized scaffolds
EA009746B1 (ru) ВАРИАНТЫ УЧАСТКА Fc
KR20120118918A (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
KR20200003235A (ko) arm-PCR 및 고속 처리 서열 분석을 이용한 항원 특이적 후천성 면역 반응의 확인
CN118878683A (zh) 靶向人dll3的嵌合抗原受体t细胞及其应用
FI115838B (fi) Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen
CN112225813A (zh) 针对破伤风毒素的抗体及其用途
WO2008095504A1 (en) A polyclonal antibody product
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
CN118146363B (zh) 一种以parp9蛋白为靶点的全人源拮抗抗体及其应用
WO2022142272A1 (zh) Cldn18.2抗体及其应用
CN117903299A (zh) 一种特异性识别aav-dj的纳米抗体及其应用
CN119219773A (zh) 阻断cd70-cd27信号轴的抗人cd70纳米抗体及其vhh链与应用
CN112062849B (zh) Cd47拮抗剂及其用途
JP4044733B2 (ja) ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
CN119241709B (zh) Itga2单克隆抗体及其应用
CN121319202B (zh) Atp7b抗体及其应用
EP1106625A1 (en) Rhesus D specific peptide sequences

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU